A single-step radiolabeling strategy for PET, SPECT, and therapeutic radionuclides using nanoparticles as a universal chelator
Radiopharmaceuticals are a novel approach for tumor treatment, with several successful examples in the clinic. When developing this approach, the selection of the two radiometals for imaging and therapy is a key step that is determined by the availability of suitable chelators that allow their in vivo targeted use. New chelators are continuously being proposed for various applications. This large number of compounds reflects the fact that there is currently no general chelator that can complex a large number of isotopes with good yields, stable labeling even in challenging conditions, and easy conjugation to the targeting vector. Here, we demonstrate how the use of core-doped iron oxide nanomaterials can be a “universal chelator.” We have developed 10 new nano-radiopharmaceuticals with applications spanning from PET and SPECT to alpha and beta therapies. We conducted a series of in vivo proof-of-concept experiments to demonstrate the potential of this approach, which combines the best of nanomaterials with the best of nuclear medicine approaches.
Authors
- Juan Pellico (ORCID: https://orcid.org/0000-0003-2787-8641)
- Marta Cortés‐Canteli (ORCID: https://orcid.org/0000-0001-8802-4338)
- Marta Casquero‐Veiga (ORCID: https://orcid.org/0000-0003-0859-9495)
- Carlos Cerón (ORCID: https://orcid.org/0000-0002-9993-8095)
- Nuria Arias‐Ramos (ORCID: https://orcid.org/0000-0001-8983-6362)
- Pilar López‐Larrubia (ORCID: https://orcid.org/0000-0002-5141-8736)
- Miguel A. Morcillo (ORCID: https://orcid.org/0000-0002-1984-5834)
- Jesús Ruı́z-Cabello (ORCID: https://orcid.org/0000-0001-8681-5056)
- Rafael T. M. de Rosales (ORCID: https://orcid.org/0000-0003-0431-0535)
- Unai Cossío (ORCID: https://orcid.org/0000-0002-3248-8683)
- Marta Oteo (ORCID: https://orcid.org/0000-0002-2855-3403)
- Eduardo Romero (ORCID: https://orcid.org/0000-0003-1347-1947)
- Lucía Gutiérrez (ORCID: https://orcid.org/0000-0003-2366-3598)
- Ana González-Paredes (ORCID: https://orcid.org/0000-0002-3504-0841)
- Fernando Herranz (ORCID: https://orcid.org/0000-0002-3743-0050)
- Victor Manuel Luján-Rodríguez
- Aitor Herraiz (ORCID: https://orcid.org/0000-0002-1018-6692)
- Andrea Rodríguez-San-Pedro
Institutions
- Ikerbasque (ES)
- Universidad Complutense de Madrid (ES)
- King's College London (GB)
- Universidad de Alcalá (ES)
- Universidad de Zaragoza (ES)
- Instituto de Salud Carlos III (ES)
- Spanish National Centre for Cardiovascular Research (ES)
- CIC biomaGUNE (ES)
- Instituto de Investigaciones Biomédicas Sols-Morreale (ES)
- Instituto de Ciencia de Materiales de Sevilla (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (ES)
- Centre for Biomedical Network Research on Rare Diseases (ES)
- Instituto de Química Médica (ES)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Instituto de Nanociencia y Materiales de Aragón (ES)
- Institut de Ciència de Materials de Barcelona (ES)
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (ES)
- Universidad Autónoma de Madrid (ES)
Publication Details
- Journal
- ChemRxiv
- Published
- 2025-08-22
- DOI
- https://doi.org/10.26434/chemrxiv-2025-lx5qj-v2
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00